 |
VasoMedical’s BIOX Instruments Receives “Excellent Trusted Enterprise” Award |
Top Award Given by Jiangsu Province SFDA of China
WESTBURY, N.Y., March 27, 2013 - VasoMedical, Inc. (“VasoMedical”) (OTC BB: VASO), a diversified medical technology company specializing in the design, manufacture and sale of medical devices for noninvasive cardiology, including EECP® Therapy systems – the gold standard of ECP therapy – announced today that Jiangsu Province State Food and Drug Administration (SFDA) of China has awarded BIOX Instruments Co., Ltd., a subsidiary of VasoMedical, with the Excellent Trusted Enterprises Award (top tier).
In consideration for this biannual award, honoring superiority in the industry, medical device companies from across the Jiangsu Province were evaluated by SFDA offices at county, city and province levels for their integrity, honesty and compliance. The finalist selection was also subject to public critique. This year, only six companies in the Wuxi region of the Jiangsu Province were recipients of this top tier award for 2011-2012, including VasoMedical's BIOX Instruments and GE Healthcare Clinical Systems (Wuxi).
"This highly prestigious award is a testament to the superior service and dedication that BIOX professionals have provided our customers throughout the past decade,” stated Mr. Qiuming Shen, president of BIOX Instruments. “SFDA's core criteria in evaluating organizations – innovation and promoting medical development – are areas that we focus on every day to ensure that we are meeting our clients' needs and positively impacting their businesses.”
“BIOX was previously selected for the Trusted Enterprises Award (second tier) in 2009-2010. Thanks to constant improvements in our technology, we are pleased to be awarded with a top tier spot this year,” Mr. Shen stated. “We will continue to build on our achievements and we are committed to facilitating growth not only within BIOX Instruments, but also as part of the VasoMedical group of companies. The success of BIOX has been propelled by VasoMedical as well as by the support from the Jiangsu business community.”
For more information, visit Jiangsu Province SFDA's website at: http://www.jsfda.gov.cn/art/2013/3/18/art_23_106245.html or BIOX Instruments' website at: www.biox.com.cn.
About VasoMedical
VasoMedical, Inc. is a diversified medical technology company specializing in the manufacture and sale of medical devices and in the domestic sale of diagnostic imaging products. The Company's main proprietary products are EECP® Therapy systems, the gold standard of ECP treatment. The Company operates through three wholly owned subsidiaries: VasoSolutions, VasoMedical Global and VasoHealthcare. VasoSolutions manages and coordinates the design, manufacture and sales of EECP® Therapy systems, and other medical equipment operations; VasoMedical Global operates the Company's China-based subsidiaries; and VasoHealthcare is the operating subsidiary for the exclusive sales representation of GE Healthcare diagnostic imaging products in certain market segments. Additional information is available on the Company's website at www.vasomedical.com.
About BIOX Instruments
BIOX Instruments Co., Ltd., a wholly owned subsidiary of VasoMedical, is based in Wuxi, Jiangsu Province, China. With long established expertise in miniaturization and low power consumption medical devices, it is a leading company in ambulatory monitoring systems consisting of ECG Holter recorders, ambulatory blood pressure monitoring (ABPM) systems as well as related analysis and reporting software. BIOX is in full compliance of revered quality and manufacturing standards such as ISO 13485, ISO 9001, US FDA cGMP as well as the Medical Device Directive of the European Union. BIOX products are FDA Cleared, CE Marked and Health Canada Listed. Furthermore, Biox continues to provide OEM and OED services to many businesses that require effective solutions to product design and performance. Additional information is available on the Company's website at www.biox.com.cn.
Except for historical information contained in this release, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this release, words such as “anticipates”, “believes”, “could”, “estimates”, “expects”, “may”, “plans”, “potential” and “intends” and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company's management, as well as assumptions made by and information currently available to the Company's management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions; the effect of the dramatic changes taking place in the healthcare environment; the impact of competitive procedures and products and their pricing; medical insurance reimbursement policies; unexpected manufacturing or supplier problems; unforeseen difficulties and delays in the conduct of clinical trials and other product development programs; the actions of regulatory authorities and third-party payers in the United States and overseas; uncertainties about the acceptance of a novel therapeutic modality by the medical community; continuation of the GEHC agreement; and the risk factors reported from time to time in the Company's SEC reports. The Company undertakes no obligation to update forward-looking statements as a result of future events or developments.
Investor Contacts:
Todd Fromer / Garth Russell
KCSA Strategic Communications
212-896-1215 / 212-896-1250
tfromer@kcsa.com / grussell@kcsa.com
Media Contacts:
Lewis Goldberg / Samantha Wolf
KCSA Strategic Communications
212-896-1216 / 212-896-1220
lgoldberg@kcsa.com / swolf@kcsa.com